Role of Genomic Alterations in HER2 Positive Breast Carcinoma: Focus on Susceptibility and Trastuzumab-therapy

E-ISSN： 1873-5576|17|4|344-356

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.17, Iss.4, 2017-04, pp. : 344-356

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacodiagnostic Testing in Breast Cancer: Focus on HER2 and Trastuzumab Therapy

By Bartlett John M.S.

American Journal of PharmacoGenomics, Vol. 5, Iss. 5, 2005-01 ,pp. : 303-315

Adis International

Access to resources Recommend Favorite

Preoperative trastuzumab, docetaxel and carboplatin therapy is effective for HER2-positive breast cancer

Inpharma, Vol. 1, Iss. 1592, 2007-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer

By Gullo Giuseppe Bettio Daniela Torri Valter Masci Giovanna Salvini Piermario Santoro Armando

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 179-183

Springer Publishing Company

Access to resources Recommend Favorite

Trastuzumab: In HER2 and Hormone Receptor Co-Positive Metastatic Breast Cancer

By Orman Jennifer S. Perry Caroline M.

Drugs, Vol. 67, Iss. 18, 2007-01 ,pp. : 2781-2789

Adis International

Access to resources Recommend Favorite

HER-2-positive metastatic breast cancer: trastuzumab and beyond

By Metro Giulio Mottolese Marcella Fabi Alessandra

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 15, 2008-10 ,pp. : 2583-2601

Informa Healthcare

Access to resources Recommend Favorite